Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d) Agreement Preface Annual Net Sales 1.08(a)(ii) Appraisal Rights Payments 7.02 Basket 7.03(a) Black Out Period 5.06(g) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(v) Closing 1.02 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(vi) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(a) Company Stock Plans 2.13(i) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(i) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(ii) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(a) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05 (a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Financial Statements 3.07(b) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix) (a) Third Party Payments 1.08(a)(xxx) Upfront Payments 1.08(xxxi)
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined As used in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d, the following terms have the respective meanings set forth below. Accommodator 2.7 Action 3.9 Affiliate Transaction 3.19(a) Agreement Preface Annual Net Sales 1.08(a)(iiPreamble Allocation 5.4(b) Appraisal Rights Payments 7.02 Basket 7.03(aAllocation Schedule 5.4(b) Black Out Period 5.06(gApprovals 2.11 Assignment Agreement and ▇▇▇▇ of Sale 2.9(f) Cancelled Shares 1.05(aAssumed Liabilities 2.5 Audited Financial Statements 3.4(a)(i) Celldex Compound 1.08(a)(iiiBuildings and Improvements 2.3(e) Celldex Early Stage Compound 1.08(a)(ivBusiness Permits 3.10(a)(i) Certificate 1.06(cCap 6.4(b) Certificate of Merger 1.01(bCitree Balance Sheet 3.4(a)(iii) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vCitree Financial Statements 3.4(a)(iii) Closing 1.02 2.2 Closing Date 1.02 2.2 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Purchase Price 2.1(a) Closing Statement 1.12 Combination Product 1.08(a)(xiii2.8 Controlling Party 5.4(c) Commercially Reasonable Efforts 1.08(a)(viCrop Insurance 2.3(r) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aDe Minimis Amount 6.4(a) Company Stock Plans 2.13(iDeductible 6.4(a)(ii) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(i) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(aDirect Claim 6.3(d) Dispute Notice 1.12(b2.14(b) Dispute Resolution Period 7.04(c2.14(b) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(viiDraft Allocation 5.4(b) European Market 1.08(a)(viiiEmployee Leasing Losses 5.2(g) Enforceability Exceptions 2.03(c3.3 Escrow Agent 2.9(c) Escrow Agreement 2.12(a) Escrow L/C Expiration 2.12(d) Escrow Letter of Credit 2.9(c) Estimated Amounts 2.8 Estimated Closing Cash 1.11 Adjustment Amount 2.8 Exchange Agent 1.06(a) Act 5.7 Excluded Assets 2.4 Financial Statements 2.05(a3.4(a) Firm 12.18 First Effective Time 1.01(bFraud Determination 6.2(a)(ii) First Kolltan Commercial Milestone 1.08(b)(iiFull Draw Event 2.12(d) First Merger 1.01(aFundamental Representation Losses 6.4(a) Health Benefits 5.08 IND 1.08(a)(ixGeneral Partner Preamble Governmental Approvals 2.11 ▇▇▇▇▇▇ Road Partners Balance Sheet 3.4(a)(iv) IND Enabling Study 1.08(xHMS 2.3(g) Identified Assets 2.7 Indemnified Party 6.3(a) Indemnity Cap 7.03(aEscrow Account 2.12(a) Independent Accountant 1.12(bAccounting Firm 2.14(b) Initial Registration Shares 5.06(aIndemnity Release Amount 2.13(a) Initiated 1.08(a)(xiInitial Indemnity Release Date 2.13(a) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiiiInterim Projected Indemnity Amount 2.13(d)(i) Latest Balance Sheet 2.05(a3.4(a)(ii) Leased Employees 5.2(a) Leased Real Property 2.07(a2.3(c) Letter of Transmittal 1.06(dLiabilities 3.5 Liability Insurance Coverage 5.2(f) Licensed Intellectual Property 2.10(c3.7(a)(ix) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xivLimited Partner Preamble Loss 6.2(b) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi3.7(a) New Debt 2.06(cPlans 5.3(b) New Debt Conversion Shares 1.14(bNon-Controlling Party 5.4(c) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(dOld Plans 5.3(b) Owned Real Property 2.3(b) Owners Preamble Parties Preamble Partnership Preamble Partnership 401(k) Plans 5.3(d) Partnership Disclosure Schedules Article 3 Partnership Documents 3.2(a) Partnership Indemnitee 6.2(c) Party Preamble Payoff Amount 5.5 Payoff Letter 5.5 Phase I Reports 3.13(a) Post-Closing Adjustment 2.14(d) Post-Closing Statement 2.14(a) Projected Indemnity Amount 2.13(a)(ii) Projected Indemnity Claim 2.13(c) Projected Indemnity Release Amount 2.13(c) Purchased Assets 2.3 Purchased Contracts 2.3(f) Purchased Intellectual Property 2.10(c2.3(g) Parent Preface Parent Financial Statements 3.07(bPurchased Leases 2.3(c)(ii) Parent SEC Documents 3.07(aPurchased Permits 2.3(n) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Purchased Real Property Leases 2.07(a2.3(d) Recommendation Withdrawal 4.03(a) Purchased Registered Intellectual Property 2.10(a3.13(a) Purchased Venture Interests 2.3(a) Purchased Venture Lease 2.3(c)(ii) Purchased Ventures 2.3(a) Purchased Ventures Accepted Liabilities 2.6 Purchased Ventures Balance Sheets 3.4(a)(iv) Purchaser Preamble Purchaser 401(k) Plan 5.3(d) Purchaser Allocation Notice 5.4(b) Purchaser Benefit Plans 5.3(b) Purchaser Claim 7.14(b) Purchaser Disclosure Schedules Article 4 Purchaser Indemnitee 6.2(b) Purchaser Material Adverse Effect 4.1(a) Regulation S-X 5.7 Related Party 1.08(a)(xxiv3.19(a) Representative Losses 10.01(eRemaining Escrow Deposit Amount 2.13(d)(i) Second Certificate Remaining Projected Indemnity Amount 2.13(d)(iii) Replacement Letter of Merger 1.01(cCredit 2.12(d) Second Effective Time 1.01(cResponsible Party 6.3(a) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(gRestricted Cash 2.3(s) Securities Act 2.04(bRetained Liabilities 2.6 Royalty-Free HMS License Agreement 2.9(g) Specified Stockholders 1.18 Stockholder Agreements 2.04(eSubleased Real Property 2.3(c)(ii) Stockholders Representative Preface Successful Completion 1.08(a)(xxvSubsequent Indemnity Release Amount 2.13(b) Superior Proposal 4.03(bSurvival Period Termination Date 6.1(a) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(aTangible Personal Property 2.3(h) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(aTax Claim 5.4(c) Third Party Payments 1.08(a)(xxxClaim 6.3(a) Upfront Payments 1.08(xxxi)Title Insurance 5.6 Title Insurer 5.6 Transaction Recitals Transferred Employees 5.3(a) Unaudited Financial Statements 3.4(a)(ii) Venture Equity Interests 3.2(a) Venture Purchase 2.11 Venture Purchase Notice 2.11 Warranty Deed 2.10(c) Workaround 2.11
Appears in 1 contract
Sources: Asset Purchase Agreement (Alico Inc)
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d2017 Calculation Period 1.06(h)(ii) 2018 Calculation Period 1.06(h)(ii) 2019 Calculation Period 1.06(h)(ii) 2020 Calculation Period 1.06(h)(ii) 2021 Calculation Period 1.06(h)(ii) AAA 9.12(a) Agreed Venue 9.12(f) Agreement Preface Annual Net Sales 1.08(a)(iiArbitration Provision 9.12(b) Appraisal Rights Payments 7.02 Basket 7.03(aAssets 3.23 Calculation Periods 1.06(h)(ii) Black Out Period 5.06(g) Cancelled Shares Closing Balance Sheet 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vClosing Date 1.03 Closing Estimates Statement 1.02(b) Closing 1.02 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Statement 1.05(a) Closing Statement 1.12 Combination Product 1.08(a)(xiiiObjection Notice 1.05(b) Commercially Reasonable Efforts 1.08(a)(viCode 3.14(a) Company Preface Company Bank Accounts 2.24 Counsel 9.16 Company Indemnification Provisions 5.01(aIntellectual Property 3.11 Deductible Amount 7.02(b) Company Stock Plans 2.13(iDebt Papers 4.25 Disclosure Schedules ARTICLE III Disputes 9.12 Disputed Items 1.07(a) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aEarn-out Amount 1.06(b) Contingency Activities 1.08(iEarn-out Objection Notice 1.06(c) D&O Indemnified Parties 5.01(aEarn-out Payment 1.06(a) D&O Tail 5.01(bEarn-out Period 1.06(h)(iii) DGCL 1.01(aEarn-out Statement 1.06(c) Dispute Notice 1.12(bEBITDA 1.06(h)(i) Dispute Period 7.04(cEBITDA Threshold Amount 1.06(h)(vi) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(viiEnvironmental Laws 3.16(a) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(cEquity Financing 4.07 Equity Financing Sources 4.07 ERISA 3.14(a) Estimated Closing Cash 1.11 Exchange Agent 1.06(aNet Working Capital 1.02(b) Financial Statements 2.05(a3.05 Financing 4.07 Fourth EBITDA Benchmark 1.06(h)(x) Firm 12.18 First Effective Time 1.01(bIndemnified Party 7.06(a) First Kolltan Commercial Milestone 1.08(b)(ii) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiiiIndemnifying Party 7.06(a) Latest Balance Sheet 2.05(a3.05 Lease 3.08(a) Leased Real Property 2.07(a) Letter of Transmittal 1.06(d3.08(a) Licensed Intellectual Property 2.10(c3.11 Losses 7.01 Major Customers 3.26(a) LockMinimum Earn-up Agreement 1.06(dout Amount 1.06(h)(x) Lock-up Persons 1.06(dMinimum EBITDA Benchmark 1.06(h)(vii) Marketing Approval 1.08(a)(xivObjection Notice 1.05(b) Material Contracts 2.09(aPDF 9.10 Pension Plan 3.14(a) Mergers 1.01(aPermit 3.19(a) Merger Sub Plan 3.14(a) Plans 3.14(a) Purchaser Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Purchaser Assets 4.27 Purchaser Intellectual Property 2.10(c4.13 Purchaser Major Customer 4.30(a) Parent Preface Parent Financial Statements 3.07(bPurchaser Latest Balance Sheet 4.07 Purchaser Lease 4.10(a) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Purchaser Leased Real Property Leases 2.07(a4.10(a) Recommendation Withdrawal 4.03(a) Registered Purchaser Licensed Intellectual Property 2.10(a4.13 Purchaser Pension Plan 4.16(a) Related Party 1.08(a)(xxivPurchaser Plan 4.16(a) Representative Losses 10.01(ePurchaser Shares 1.02(a)(i) Sale Consideration 1.02(a) Schedule ARTICLE III Seller Group 9.16(a) SEC Reports 4.07 Second Certificate of Merger 1.01(cEBITDA Benchmark 1.06(h)(viii) Second Effective Time 1.01(cServices 6.07(a)(ii) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(gStock Preface Stockholder Preface Tangible Personal Property 3.24 Tax Contest 6.02(d) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(aThird EBITDA Benchmark 1.06(h)(ix) Third Party Payments 1.08(a)(xxxClaim 7.06(a) Upfront Payments 1.08(xxxi)Unadjusted Sale Consideration 1.02(a) WARN 3.22
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Term Section No. Acquisition Agreement 4.03(dTransaction 6.05 Affiliate Contract 4.22 Affiliate Transactions 4.22(c) Agreement Preface Annual Net Sales 1.08(a)(iiPreamble Allocation Schedule 1.10 Applicable Survival Period 9.01 Audited Balance Sheet 4.06 Audited Balance Sheet Date 4.06 Audited Financial Statements 4.06 BlueCielo Purchase Agreement 2.04(a) Appraisal Rights Payments 7.02 Basket 7.03(aBlueCielo RUS 7.08 BlueCielo RUS Carveout 7.08 Cap 9.04(b) Black Out Period 5.06(g) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(cCBA 4.09(a)(xiv) Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(v) 7.07 Closing 1.02 Balance Sheet 1.11 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition 2.02 Closing Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(vi1.11 Common Stock Merger Consideration 1.02(a) Company Preface Preamble Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(a401(k) Participant 7.06(c) Company Stock 401(k) Plans 2.13(i7.06(c) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aCompany Material Contract 4.09(b) Contingency Activities 1.08(iCompany Parties 7.07 Company Person 4.22(d) Confidentiality Agreement 6.02 Continuation Period 7.06(a) CSA 7.03(c) D&O Indemnified Parties 5.01(aParty 7.02(a) D&O Tail 5.01(b7.02(b) Deductible 9.04(a) Derivative Securities 4.05(a) DGCL 1.01(a) Disclosure Schedules 11.02 Dispute Notice 1.12(b) Dispute Period 7.04(c) Resolution Arbiter 1.11 Disqualified Individual 6.08 Dissenting Share 1.09 1.14 Dissenting Stockholder 1.09 DLLCA 1.01 1.14 DSS 7.03(c) Effective Date Preface Efforts Period 1.08(a)(viiRWI Policies 4.15(b) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(ii) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(a) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Enforceability Exceptions 4.02 Escrow Account 1.13 Escrow Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Financial Statements 3.07(b) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(a) Third Party Payments 1.08(a)(xxx) Upfront Payments 1.08(xxxi)1.13 Escrow Amount 1.13
Appears in 1 contract
Sources: Transaction Agreement
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(dAggregate Company Option Consideration 1.2(d) Agreement Preface Annual Net Sales 1.08(a)(iiPreamble APPRO 401(k) Appraisal Rights Payments 7.02 Basket 7.03(aPlan 7.7(d) Black Out Period 5.06(gAudited Financial Statements 4.6 Certificate(s) Cancelled Shares 1.05(a1.4(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate of Merger 1.01(b) Claims Claim Notice 7.04(b) Clinical Trial 1.08(a)(v10.2(c)(v) Closing 1.02 2.2(a) Closing Date 1.02 2.2(a) Closing Financial Statement 2.3(b) Closing Statement 2.3(b) Common Stock Closing Cash Certificate 1.11 Closing Shortfall Closing Consideration 2.1(c) Common Stock Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiiiConsideration 1.2(b)(vii) Commercially Reasonable Efforts 1.08(a)(viCommon Stock Per Share Value 1.2(b)(viii) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aIntellectual Property Rights 4.11(a) Company Stock Plans 2.13(i) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(i) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Option Closing Cash 1.11 Consideration 2.1(e) Company Option Consideration 1.2(d) Company Option(s) 1.2(d) Compensation Agreements 4.14(a) Confidentiality Agreement 6.2 Continued Employee 7.7(b) Continuing Employee Benefit Plans 7.7(a) CPR 13.12(b) CUNA 12.1 CUNA Escrow Deposit 1.12(a) Disclosure Schedule Article 4 Dissenting Shareholder 1.6 Dissenting Shares 1.6 Effective Time 1.1(b) Environmental and Safety Requirements 4.18(a) Equifax 401(k) Plan 7.7(b)(i) Equifax Pension Plan 7.7(b)(ii) ERISA 4.14(a) Escrow Allocation Schedule 1.5(a) Escrow Deposit 1.5(a) ESOP 3.1(g)(vi) Exchange Agent 1.06(a1.4(a) Exchange Agreement 1.4(a) Exchange Fund 1.4(a) Final Allocation Schedule 1.3 Financial Statements 2.05(a4.6 Fully Diluted Per Share Value 1.2(b)(vi) Firm 12.18 First Effective Time 1.01(bFully Diluted Shares Outstanding 1.2(b)(iv) First Kolltan Commercial Milestone 1.08(b)(iiHSR Act 3.1(d) First Merger 1.01(aIndemnifiable Tax 11.4(a) Health Benefits 5.08 IND 1.08(a)(ixIndemnified Party 10.2(c)(i) IND Enabling Study 1.08(xIndemnifying Party 10.2(c) Indemnity Cap 7.03(aFund 1.5(a) Indemnity Notice 10.2(c)(vi) Independent Accountant 1.12(bAccounting Firm 2.3(c) Initial Registration Shares 5.06(aInformation Statement 6.8 Insurance Policies 4.15 Intellectual Property Rights 4.11(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) LBCL Recitals Latest Balance Sheet 2.05(a4.6 Licenses 4.17 Losses 10.2(a) Leased Real Property 2.07(aMerger Recitals Majority in Interest 1.11(a) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(aMerger Consideration 2.1(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Preamble Most Recent Financial Statements 3.07(b4.6 Notice Period 10.2(c)(i) Optionholder(s) 1.3 Optionholder Certificates 1.4(a) Original Disclosure Schedules 6.5(a) Outstanding Receivables 8.11 Parent SEC Documents 3.07(aPreamble Parent Representatives 6.2 Parent Schedule Article 5 Pension Plan 4.14(c) Parent Stock Value 1.08(a)(xiPlans 4.14(a) Parties Preface Partnership Agreement 1.08(a)(xviiPost-Closing Operating Capital Adjustment 2.3(a) Permits 2.15(cPost-Closing Adjustment Calculation 2.3(b) Phase I Clinical Trial 1.08(a)(xxPost-Closing Adjustment Fund 1.5(a) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxixPre-Closing Operating Capital Adjustment 2.2(b)
(a) Third Party Payments 1.08(a)(xxx) Upfront Payments 1.08(xxxi)
Appears in 1 contract
Sources: Merger Agreement (Equifax Inc)
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d) Agreement Preface Annual Net Sales 1.08(a)(ii) Appraisal Rights Payments 7.02 Basket 7.03(a) Black Out Period 5.06(g) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(v) Closing 1.02 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(vi) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(a) Company Stock Plans 2.13(i) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(i) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(ii) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(a) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05. Term Section No. ---- -----------
(a) Other Active 1.08(a)(xviiAdjustment 10.03 Adjustment Amount Due 1.04(a) Outside Date 9.01(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Financial Statements 3.07(b) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)Adjustment Schedule 1.04
(a) Affiliate Intellectual Property 1.01(b) Affiliate Seller(s) 1.01(b) Agreement Preamble Allocation 1.05 Approval Notice 1.04(b)(i) Term Section No. ---- ----------- Audited Financial Statements 2.09 Business 6.02 Closing Date Working Capital Amount 1.04(a) Company Preamble Company Intellectual Property 2.15 Contest 10.02(b) Direct Claim 9.03(b) Dispute Period 1.04(b) Dispute Notice 1.04(b)(ii) Disputes 9.05(a) Disputing Person 9.05(b) FFDC Act 2.27(b) Final Determination 9.05(e) GN 2.27(d) GP Act 2.03 GP Agreement 2.03 Indemnified Party 9.03 Indemnifying Party 9.03 Independent Accountant 1.04(b) Independent Accountant Determination 1.04(b) Independent Accountant Tax Effect Determination 9.01(b)(ii) Intellectual Property 2.15 Interest Rate 1.04(b) Interests Preamble Interim Financial Statements 4.09 Joint Defense Proceeding 9.03(a)(ii) LLC Act 2.03 LLC Agreement 2.03 Most Recent Balance Sheet 2.09 Newco 1 LLC Preamble Newco DGP1 Preamble NFS Preamble Notice of Arbitration 9.05(b) Numico USA Preamble Purchase Price 1.02 Purchaser Preamble Purchaser Arbitrator 9.05(c) Term Section No. ---- -----------
(a) Seller Losses 9.02
(a) Tax Effect Approval Notice 9.01(b)(ii) Tax Effect Dispute Notice 9.01(b)(ii) Tax Effect Dispute Period 9.01(b)(ii) Tax Effect Remaining Disputes 9.01(b)(ii) Tax Effect Resolution Period 9.01(b)(ii) Third Party Payments 1.08(a)(xxxClaim 9.03(a)(i) Upfront Payments 1.08(xxxiTransferees 4.05 WC Target 1.04
(a) Working Capital Assets 1.04(b) Working Capital Liabilities 1.04(b)
Appears in 1 contract
Sources: Purchase Agreement (Nbty Inc)
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(dAggregate Closing Consideration 1.02(a) Agreement Preface Annual Net Sales 1.08(a)(iiPreamble Audited Balance Sheet 4.05(b) Appraisal Rights Payments 7.02 Basket 7.03(a) Black Out Period 5.06(g) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vBuyer Preamble Buyer Indemnitees 10.02 Buyer’s Representatives 6.02 Claiming Party 10.07(a) Closing 1.02 1.04 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition 1.04 Closing Statement 1.12 Combination Product 1.08(a)(xiii1.02(c) Commercially Reasonable Efforts 1.08(a)(viCode 4.12(a) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aPreamble Confidentiality Agreement 6.02 Consent Solicitation 1.03(a) Company Stock Plans 2.13(iDebt Commitment Letters 5.08 Defending Party 10.07(a) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aDisputed Items 1.02(d) Contingency Activities 1.08(iEnvironmental and Safety Requirements 4.15(a) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(cEquity Commitment Letter 5.08 ERISA 4.12(a) Estimated Aggregate Closing Cash 1.11 Exchange Agent 1.06(aConsideration 1.02(b) Estimated Net Working Capital 1.02(b) Financial Statements 2.05(a4.05(b) Firm 12.18 First Effective Time 1.01(bHazardous Materials 4.15 Independent Auditor 1.02(d) First Kolltan Commercial Milestone 1.08(b)(ii) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Intellectual Property Licenses 4.10 Latest Balance Sheet 2.05(a4.05(b) Leased Real Property 2.07(a4.07(b) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Losses 10.02 Merger 6.07 Merger Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(a) 6.07 Merger Sub Preface METRIC Study 1.08(a)(xv6.07 Note Tender Offer 1.03(a) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(dObjections Statement 1.02(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Financial Statements 3.07(b) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a4.07(b) Recommendation Withdrawal 4.03(aPBGC 4.12(b) Registered Intellectual Property 2.10(aPension Plans 4.12(a) Related Party 1.08(a)(xxivPlans 4.12(a) SEC 4.05(a) SEC Reports 4.05(a) Seller Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(a) 9.01 Sellers Preamble the Company’s knowledge 12.03 Third Party Payments 1.08(a)(xxxClaim 10.07(a) Upfront Payments 1.08(xxxiWelfare Plans 4.12(a)
Appears in 1 contract
Sources: Unit Purchase Agreement (Alliance Laundry Systems LLC)
Cross-Reference of Other Definitions. Each capitalized term listed of the terms set forth in the table below is defined in the corresponding Section of this AgreementAgreement set forth opposite such term: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d2010 MIP Amounts 5.15 Accounts Receivable 2.3(l) Agent Claim 7.9(b) Agreement Preface Preamble Annual Net Sales 1.08(a)(iiFinancial Statements 2.3(j)(i) Appraisal Rights Payments 7.02 Basket 7.03(aArbitrating Accountant 1.7(b) Black Out Period 5.06(gBank Accounts 2.3(y) Cancelled Shares 1.05(aBenefit Plan(s) Celldex Compound 1.08(a)(iii2.3(q)(i) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vBusiness Recitals Canadian Participants 5.15 Closing 1.4(a) Closing 1.02 Date 1.4(a) Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Closing Purchase Price Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(vi1.6 Code 2.3(m)(i) Company Preface Preamble Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aAssets 2.3(k)(i) Company Stock Plans 2.13(iBonds and Letters of Credit 5.8(b) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aCorporate Contracts 5.9(a) Contingency Activities 1.08(iDamages 7.2(a) D&O Indemnified Parties 5.01(aDeductible 7.4(b) D&O Tail 5.01(b) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Delivery Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(ii) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(a) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.051.6 Disclosure Schedule 2.1
(a) Other Active 1.08(a)(xviiDispute Notice 1.7(a) Outside Dispute Period 1.7(a) Effective Time 1.4(a) Election 4.8(a) Election Termination Date 9.01(d4.8(c) Owned Intellectual Property 2.10(cEmployee(s) Parent Preface Parent 6.1 ERISA 2.3(q)(i) Estimated Purchase Price 1.5(a) ETS Canada Recitals Excluded Marks 5.7 Exel Trucking Recitals Financial Statements 3.07(b2.3(j)(i) Parent SEC Documents 3.07(aFundamental Representations 7.2(d) Parent Stock Value 1.08(a)(xiHSR Act 2.2(c) Indemnified Party 7.2(b) Indemnifying Party 7.2(c) Insurance Policies 2.3(z)(i) Interim Financial Statements 2.3(j)(i) Leased Real Estate 2.3(u)(i) Leases 2.3(u)(ii) Material Contracts 2.3(o) MIP 5.15 Negotiation Period 1.7(b) Net Working Capital Example 1.6 Permits 2.3(p)(i) Post-Closing Straddle Period 4.3 Potential Claims 5.6 Pre-Closing Straddle Period 4.3 Pre-Closing Tax Returns 4.1(a) Prevailing Party 1.7(b) Purchase Price 1.2 Purchase Price Allocation 4.8(b) Purchaser Preamble Purchaser Deductible 7.6(b) Purchaser Indemnitees 7.3 Purchaser Prepared Returns 4.1(b) Purchaser Released Claims 5.9(a) Purchaser Released Parties Preface Partnership Agreement 1.08(a)(xvii5.9(a) Permits 2.15(cRecoverable Damages 7.7(b) Phase I Clinical Trial 1.08(a)(xxSection 338 Forms 4.8(a) Phase II Clinical Trial 1.08(a)(xxiSeller Preamble Seller Group Returns 4.1(a) Phase III Clinical Trial 1.08(a)(xxiiSeller Indemnities 7.5 Seller Occurrence Policies 5.6 Seller Owned Property 2.3(u)(v) Product Transferee 1.08(a)(xxiiiSeller Prepared Returns 4.1(a) Proprietary Software 2.10(iSeller Released Claims 5.9(b) Prospectus Supplement 5.06(bSeller Released Parties 5.9(b) Real Property Leases 2.07(aSeller’s Bonds and Letters of Credit 5.8(a) Recommendation Withdrawal 4.03(aShares Recitals Specified Third Party 7.7(b) Registered Intellectual Property 2.10(aStraddle Period 4.1(b) Related Party 1.08(a)(xxivStraddle Tax Returns 4.1(b) Representative Losses 10.01(eSubsidiaries or Subsidiary Recitals Survival Period 7.2(e) Second Certificate of Merger 1.01(cTax 2.3(m)(i) Second Effective Time 1.01(cTax Contest 4.5 Tax Returns 2.3(m)(i) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(aTaxes 2.3(m)(i) Third Party Payments 1.08(a)(xxxClaim 7.2(f) Upfront Payments 1.08(xxxi)Title IV Representations 7.2(g) Transaction Bonuses 5.11 Transfer Taxes 4.6 Working Capital Target 1.3
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: Term Section No. 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(dArrangements 4.12(d) Accounting Firm 1.09(b) Agreement Preface Annual Net Sales 1.08(a)(iiAlternative Arrangements 8.06(a) Appraisal Rights Payments 7.02 Basket 7.03(aBalance Sheet Date 4.05 Base Consideration 1.02(c) Black Out Period 5.06(g) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) CERCLA 11.01 Certificate of Merger 1.01(b) Claims Notice 7.04(bClaiming Party 12.20 Class A Merger Consideration 1.02(a) Clinical Trial 1.08(a)(vClass B Merger Consideration 1.02(b) Closing 1.02 1.10 Closing Balance Sheet 1.09(a) Closing Date 1.02 1.10 Closing Residual Cash Certificate 1.11 Consideration 1.02(c) Closing Shortfall Closing Merger Shares definition Residual Cash Consideration Calculation 1.08 Closing Statement 1.12 Combination Product 1.08(a)(xiii1.09(a) Commercially Reasonable Efforts 1.08(a)(vi) Closing Transactions 2.01 Company Preface Company Bank Accounts 2.24 Employees 7.03 Company Indemnification Provisions 5.01(aRegistered Intellectual Property 4.10(a) Company Stock Plans 2.13(iConfidentiality Agreement 6.02 Copyrights 11.01 Defending Party 12.20 Designated Contacts 6.02 DGCL Preamble Disclosure Schedules Article IV Disputed Items 1.09(b) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(iDissenting Shares 1.11 D&O Costs 7.02(b) D&O Indemnified Parties 5.01(aExpenses 7.02(b) D&O Indemnifiable Claim 7.02(b) D&O Indemnifying Party 7.02(b) D&O Indemnitee 7.02(b) D&O Tail 5.01(bPolicies 7.02(c) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(iiElectronic Delivery 12.16 ERISA 4.12 Escrow Agreement 2.01(d) First Merger 1.01(aFinal Residual Cash Consideration 1.02(d) Health Benefits 5.08 IND 1.08(a)(ixFinancial Statements 4.05 Foreign Benefit Plan 4.12(i) IND Enabling Study 1.08(xInbound IP Contracts 4.10(k) Indemnity Cap 7.03(aIndemnitee 8.05 Indemnitor 8.05 IP Contracts 4.10(k) Independent Accountant 1.12(bKey Technology Offerings 4.10(i) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Knowledge 12.04 Latest Balance Sheet 2.05(a) 4.05 Leased Real Property 2.07(a4.18(b) Letter of Transmittal 1.06(d1.03 Loss 8.02(a) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(aMarks 11.01 Merger Preface Merger Consideration 1.02(b) Merger Sub Preface METRIC Study 1.08(a)(xvNew Plans 7.03 Non-Accelerated Equity 6.01(a) Objections Statement 1.09(b) Off-the-Shelf Software 4.10(k) Option Cancellation Agreement 1.04 Option Merger Sub II Preface Milestone 1.08(bConsideration 1.04 Optionholder 1.04 Options 1.02(f) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Intellectual Property 2.10(cOutbound IP Contract 4.10(k) Parent Preface Parent Financial Statements 3.07(bIndemnified Parties 8.02(a) Parent SEC Documents 3.07(aParent’s Representatives 6.02 Patents 11.01 Paying Agent Agreement 2.01(b) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxixPer Share Portion 1.02(e)
(a) Pre-Closing Tax Refund 10.01(a)(iv) Representative Preface Schedule Article IV Securities Act 5.07 Seller Indemnified Parties 8.03(a) Stockholder 1.03 Stockholder Approval 10.02 Stockholder Group 10.05 Significant Contract(s) 4.09(a) Surviving Corporation 1.01(a) Systems 4.10(l) Third Party Payments 1.08(a)(xxx) Upfront Payments 1.08(xxxiClaim 8.05 Trade Secrets 11.01 Transfer Taxes 10.01(d)
Appears in 1 contract
Sources: Merger Agreement (Belden Inc.)
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Transaction 6.09 Agreement 4.03(d) Agreement Preface Annual Net Sales 1.08(a)(ii) Appraisal Rights Payments 7.02 Basket Preamble Alternative Arrangement 7.03(a) Black Out Period 5.06(gAnnouncement Press Release 10.02 Anti-Bribery Laws 4.21(a) Audited Financial Statements 4.05 Burdensome Condition 6.04(c) Cancelled Shares 1.05(a2.02(a)(iii) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(ivCBA 4.11(a)(xii) Certificate 1.06(c2.04(a) Certificate of Merger 1.01(b2.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vCharges 10.20(d) Closing 1.02 3.01 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(vi3.01 Common Stock 4.03(a) Company Preface Preamble Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(a401(k) Company Stock Plans 2.13(iPlan 7.03(f) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aConsultation Period 2.09(d) Contingency Activities 1.08(iContinuation Period 7.03(a) Continuing Employees 7.03(a) Current Insurance 7.02(c) D&O Indemnified Parties 5.01(aExpenses 7.02(b) D&O Indemnifiable Claim 7.02(b) D&O Indemnifying Party 7.02(b) D&O Indemnitee 7.02(a) D&O Tail 5.01(bInsurance 7.02(c) Data Security Requirements 4.13(e) Designated Contacts 6.02 DGCL 1.01(a2.01(a) Dispute Notice 1.12(bDisputed Items 2.09(d) Dispute Period 7.04(cDisqualified Individual 7.05 Dissenting Shares 2.10 DOJ 6.04 Effective Time 2.01(b) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(viiElectronic Delivery 10.15 Environmental Authorizations 4.19(a) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(cEscrow Agreement 3.02(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(aStatement 2.08 Estimated Merger Consideration 2.08 Ex-Im Laws 4.21(b) Financial Statements 2.05(aFinal Closing Statement 2.09(e) Firm 12.18 First Effective Time 1.01(bFinal Merger Consideration 2.09(e) First Kolltan Commercial Milestone 1.08(b)(iiFinal Overage 2.09(f) First Merger 1.01(aFinal Underage 2.09(g) Health Benefits 5.08 IND 1.08(a)(ixFinancing 6.07(a) IND Enabling Study 1.08(xFTC 6.04 Governmental Approvals 6.04 Healthcare Reform Laws 4.16(h) Indemnity Cap 7.03(aHolder Income or Indirect Taxes 7.04(b) Independent Accountant 1.12(bImprovements 4.14(d) Initial Registration Shares 5.06(aInsured Persons 7.02(c) Initiated 1.08(a)(xiIntermediary Transaction Tax Shelter 7.04(f) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(aIn-the-Money Option 2.03 Labor Organization 4.15(a) Letter of Transmittal 1.06(d2.04(a) Licensed Intellectual Property 2.10(c) LockMajority-up Agreement 1.06(d) LockIn-up Persons 1.06(d) Marketing Approval 1.08(a)(xivInterest 10.20(f) Material Contracts 2.09(a4.11(a) Mergers 1.01(aMaterial Customers 4.22 Material Suppliers 4.22 Merger 2.01(a) Merger Sub Preface METRIC Study 1.08(a)(xvPreamble Most Recent Financial Statements 4.05 New Plans 7.03(g) Merger Sub II Preface Milestone 1.08(bNon-Party Affiliates 10.21 Non-U.S. Plan 4.16(g) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xviiOriginal Outside Date 9.01(d) Outside Date 9.01(d) Outside Date Extension 9.01(d) Owned Intellectual Real Property 2.10(c4.14(a) Parcel 4.14(a) Parent Preface Preamble Parent Financial Statements 3.07(b401(k) Parent SEC Documents 3.07(aPlan 7.03(f) Parent Parent’s Representatives 6.02 Payoff Letters 3.03(b)(ii) Post-Closing Statement 2.09(a) Preferred Stock Value 1.08(a)(xi4.03(a) Parties Preface Partnership Agreement 1.08(a)(xviiPreliminary Cash 2.09(a) Permits 2.15(cPreliminary Indebtedness 2.09(a) Phase I Clinical Trial 1.08(a)(xxPreliminary Merger Consideration 2.09(a) Phase II Clinical Trial 1.08(a)(xxiPreliminary Net Working Capital 2.09(a) Phase III Clinical Trial 1.08(a)(xxiiPreliminary Transaction Expenses 2.09(a) Product Transferee 1.08(a)(xxiiiPurchaser Arrangements 7.05 Real Property Laws 4.14(e) Proprietary Software 2.10(i) Prospectus Supplement 5.06(bReal Property Lease 4.14(b) Real Property Leases 2.07(a4.14(b) Recommendation Withdrawal 4.03(aReference Date 4.07 Registered IP 4.13(a) Registered Intellectual Property 2.10(aReview Period 2.09(c) Related Party 1.08(a)(xxivSanctioned Person 4.21(b) Representative Losses 10.01(eSanctions 4.21(b) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g7.05 Securityholder Representative Preamble Securityholder Representative Reserve Fund Amount 2.11 Settlement Accountant 2.09(d) Securities Skadden 3.01 Specified Indebtedness 3.03(b)(ii) Statement of Objections 2.09(c) Stockholder 2.04(a) Stockholder Group 7.07 Subrogation Waiver 6.08 Surviving Corporation 2.01(a) Transfer Taxes 7.04(b) Unavailable Benefit 7.03(a) Waived Benefits 7.05 WARN Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix4.15(b)
(a) Third Party Payments 1.08(a)(xxx) Upfront Payments 1.08(xxxi)
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 7.14(b) Accel-KKR 7.9 Acquisition Proposal 7.10 Adjustment Escrow Account 3.7(a) Adjustment Escrow Agreement 4.03(d3.7(a) Adjustment Escrow Deficiency Amount 3.7(f) Agreement Preface Annual Net Sales 1.08(a)(iiPreamble Authorized Action 10.20(b) Appraisal Rights Payments 7.02 Basket 7.03(aBalance Sheet 5.6(a) Black Out Period 5.06(gBalance Sheet Date 5.6(a) Cancelled Shares 1.05(aBase Purchase Price 1.1 Cap 9.2(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) CERCLA 1.1 Certificate 1.06(c3.1(g) Certificate of Merger 1.01(b2.3 Ciboodle Claim 9.5(a) Claims Notice 7.04(bCiboodle Sellers 9.5(a) Clinical Trial 1.08(a)(vClaim 7.7(c) Claiming Party 10.15 Closing 1.02 2.2 Closing Date 1.02 2.2 Closing Cash Certificate 1.11 Closing Shortfall Closing Indebtedness 1.1 Common Stock 3.1(b) Common Stock Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(viConsideration 3.1(f) Company Preface Preamble Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aBenefit Plans 5.13(a) Company Stock Plans 2.13(iCharter Documents 5.1 Company Documents 5.2(a) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aCompany Employee 5.13(a) Contingency Activities 1.08(iCompany Registered Intellectual Property 5.11(b) D&O Indemnified Parties 5.01(aCompany Statement 3.7(b) D&O Tail 5.01(bConditionally Waived 280G Benefits 7.14(b) Confidentiality Agreement 7.6 Defending Party 10.15 DGCL 1.01(a2.1 Dispute Firm 9.2(g)(ii) Dispute Notice 1.12(b) Dispute Period 7.04(cResolution Firm 3.7(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Shares 3.2(c) Domain Names 1.1 Effective Date Preface Efforts Period 1.08(a)(viiTime 2.3 Electronic Delivery 10.18 Equity Plan 3.1(c) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(cERISA 5.13(a) Estimated Cash on Hand 3.7(b) Estimated Indebtedness 3.7(b) Estimated Net Working Capital 3.7(b) Estimated Pre-Closing Taxes 3.7(b) Estimated Transaction Costs 3.7(b) Excess Amount 3.7(d) Executive Shares 3.5 Existing Policy 7.7(e) Final Cash 1.11 Exchange Agent 1.06(aon Hand 3.7(c) Final Indebtedness 3.7(c) Final Net Working Capital 3.7(c) Final Pre-Closing Taxes 3.7(c) Final Transaction Cost 3.7(c) Financial Controls 5.6(d) Financial Statements 2.05(a5.6(a) Firm 12.18 First Effective Time 1.01(bFinancing 7.13 Impermissible Failure to Close 4.3 Indemnified Party 9.3(a) First Kolltan Commercial Milestone 1.08(b)(iiIndemnifying Party 9.3(a) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(bIndemnitees 7.7(a) Initial Registration Shares 5.06(aLine Item Indemnity Period 9.2(b) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(a) Intermediary Transaction Tax Shelter 10.6 Letter of Transmittal 1.06(d3.2(a) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xivLGPL 1.1 Losses 9.1(a) Material Contracts 2.09(aCompany Products 5.11(a) Mergers 1.01(aMerger Recitals Merger Consideration 3.1(f) Merger Sub Preface METRIC Study 1.08(a)(xvPreamble Mini-Basket 9.2(a) Non-Party Affiliates 10.3 Objections Statement 3.7(c) Option Merger Sub II Preface Milestone 1.08(bConsideration 3.1(c) Milestone Abandonment Optionholder 3.1(c) Optionholder Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii3.1(c) Outside Date 9.01(d4.1(a) Owned Intellectual Real Property 2.10(c5.9(b) Parent Preface Preamble Parent Financial Statements 3.07(bClaim 9.5(a) Parent SEC Documents 3.07(aClosing Statement 3.7(c) Parent Stock Value 1.08(a)(xiClosing Statement Date 3.7(c) Parties Preface Partnership Agreement 1.08(a)(xviiParent Documents 6.2 Parent Indemnified Party 9.1(a) Permits 2.15(cPersonal Property Leases 5.10 Pre-Closing Straddle Period 7.12(d) Phase I Clinical Trial 1.08(a)(xxPre-Closing Tax Return 7.12(b) Phase II Clinical Trial 1.08(a)(xxiPre-Closing Taxes 7.12(d) Phase III Clinical Trial 1.08(a)(xxiiPrivileged Communications 10.4 Proceeding 10.15 R&W Expiration Date 9.2(d) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(bReal Property Lease 5.9(a) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv5.9(a) Representative Losses 10.01(ePreamble Representative Account 3.8 Representative Cap 9.2(b) Representative Expenses 3.8 Representative Expiration Date 9.2(d) Representative Holdback Amount 3.8 Representative Indemnification 3.8 Required by Law Exception 9.2(g)(ii) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(gLine Item Indemnity Period 9.2(b) Securities Act 2.04(b6.8 Series A Merger Consideration 3.1(d) Specified Stockholders 1.18 Stockholder Agreements 2.04(eSeries B Merger Consideration 3.1(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxvShortfall Amount 3.7(e) Superior Proposal 4.03(bSignificant Contracts 5.12(a) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(aSignificant Customer 5.21(a) Straddle Tax Period Return 7.12(b) Subsidiary Charter Documents 5.5(c) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(aCorporation 2.1 Tax Matter 7.12(c)(i) Third Party Payments 1.08(a)(xxxClaim 9.3(a) Upfront Payments 1.08(xxxi)Trade Secrets 1.1 Transfer Taxes 7.12(a) Unconditionally Waived 280G Benefits 7.14(a) Written Consent Recitals
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d) Proposal 7.05 Agreement Preface Annual Net Sales 1.08(a)(ii) Appraisal Rights Payments 7.02 Basket 7.03(a) Black Out Period 5.06(g) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Broker Agreement 4.22 Buyer Arrangements 7.08 Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(v) Closing 1.02 2.01 Closing Balance Sheet 1.08 Closing Date 1.02 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiii) Commercially Reasonable Efforts 1.08(a)(vi2.01 Code 4.13(b) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(a) Company Stock Plans 2.13(i) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(iConfidentiality Agreement 7.02 Conversions 7.09 Covered Claim 8.02(a) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(bIndemnitees 8.02(a) DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(c) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Resolution Arbiter 1.08 Disclosure Schedules 12.01 Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(iiEnvironmental and Safety Requirements 4.16(a) First Merger 1.01(a) Health Benefits 5.08 IND 1.08(a)(ix) IND Enabling Study 1.08(x) Indemnity Cap 7.03(a) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xi) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(a) Leased Real Property 2.07(a) Letter of Transmittal 1.06(d) Licensed Intellectual Property 2.10(c) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Financial Statements 3.07(b) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxixERISA 4.13(b)
(a) Third Party Payments 1.08(a)(xxxEstimated Tangible Net Worth 1.07(a) Upfront Payments 1.08(xxxiFinancial Statements 4.04 HSR Act 4.12 Information Practices 4.24 Intellectual Property 4.10 K&E 12.02 Latest Balance Sheet 4.04 Leased Real Property 4.07(b) Material Contracts 4.09(c) Maximum Premium 8.02(b) Merger Recitals Merger Sub Preface Objections Statement 1.08 Outside Date 9.01(f) Parent Preface Parent Approval 3.02(g)(ii) Parent Disclosure Letter Article V Parent Indemnified Parties 11.01 Parent’s Representative 7.02 Pension Plans 4.13(b) Permits 4.15 Preliminary Statement 1.08 Recent SEC Reports Article V Schedule 12.01 Stockholder Preface Stockholder Approval 3.01(j)(ii) Stockholder Group 7.05 Surviving Corporation 1.01(a) Welfare Plans 4.13(b)
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined As used in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d, the following terms have the respective meanings set forth below. Term Section Accommodator 2.7 Action 3.9 Affiliate Transaction 3.19(a) Agreement Preface Annual Net Sales 1.08(a)(iiPreamble Allocation 5.4(b) Appraisal Rights Payments 7.02 Basket 7.03(aAllocation Schedule 5.4(b) Black Out Period 5.06(gApprovals 2.11 Assignment Agreement and ▇▇▇▇ of Sale 2.9(f) Cancelled Shares 1.05(aAssumed Liabilities 2.5 Audited Financial Statements 3.4(a)(i) Celldex Compound 1.08(a)(iiiBuildings and Improvements 2.3(e) Celldex Early Stage Compound 1.08(a)(ivBusiness Permits 3.10(a)(i) Certificate 1.06(cCap 6.4(b) Certificate of Merger 1.01(bCitree Balance Sheet 3.4(a)(iii) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vCitree Financial Statements 3.4(a)(iii) Closing 1.02 2.2 Closing Date 1.02 2.2 Closing Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Purchase Price 2.1(a) Closing Statement 1.12 Combination Product 1.08(a)(xiii2.8 Controlling Party 5.4(c) Commercially Reasonable Efforts 1.08(a)(viCrop Insurance 2.3(r) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aDe Minimis Amount 6.4(a) Company Stock Plans 2.13(iDeductible 6.4(a)(ii) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(i) D&O Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(aDirect Claim 6.3(d) Dispute Notice 1.12(b2.14(b) Dispute Resolution Period 7.04(c2.14(b) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(viiDraft Allocation 5.4(b) European Market 1.08(a)(viiiEmployee Leasing Losses 5.2(g) Enforceability Exceptions 2.03(c3.3 Escrow Agent 2.9(c) Escrow Agreement 2.12(a) Escrow L/C Expiration 2.12(d) Escrow Letter of Credit 2.9(c) Estimated Amounts 2.8 Estimated Closing Cash 1.11 Adjustment Amount 2.8 Exchange Agent 1.06(a) Act 5.7 Excluded Assets 2.4 Financial Statements 2.05(a3.4(a) Firm 12.18 First Effective Time 1.01(bFraud Determination 6.2(a)(ii) First Kolltan Commercial Milestone 1.08(b)(iiFull Draw Event 2.12(d) First Merger 1.01(aFundamental Representation Losses 6.4(a) Health Benefits 5.08 IND 1.08(a)(ixGeneral Partner Preamble Governmental Approvals 2.11 ▇▇▇▇▇▇ Road Partners Balance Sheet 3.4(a)(iv) IND Enabling Study 1.08(xHMS 2.3(g) Identified Assets 2.7 Indemnified Party 6.3(a) Indemnity Cap 7.03(aEscrow Account 2.12(a) Independent Accountant 1.12(bAccounting Firm 2.14(b) Initial Registration Shares 5.06(aIndemnity Release Amount 2.13(a) Initiated 1.08(a)(xiInitial Indemnity Release Date 2.13(a) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiiiInterim Projected Indemnity Amount 2.13(d)(i) Latest Balance Sheet 2.05(a3.4(a)(ii) Leased Employees 5.2(a) Leased Real Property 2.07(a2.3(c) Letter of Transmittal 1.06(dLiabilities 3.5 Liability Insurance Coverage 5.2(f) Licensed Intellectual Property 2.10(c3.7(a)(ix) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xivLimited Partner Preamble Loss 6.2(b) Material Contracts 2.09(a) Mergers 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xv) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi3.7(a) New Debt 2.06(cPlans 5.3(b) New Debt Conversion Shares 1.14(bNon-Controlling Party 5.4(c) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(dOld Plans 5.3(b) Owned Real Property 2.3(b) Owners Preamble Parties Preamble Partnership Preamble Partnership 401(k) Plans 5.3(d) Partnership Disclosure Schedules Article 3 Partnership Documents 3.2(a) Partnership Indemnitee 6.2(c) Party Preamble Payoff Amount 5.5 Payoff Letter 5.5 Phase I Reports 3.13(a) Post-Closing Adjustment 2.14(d) Post-Closing Statement 2.14(a) Projected Indemnity Amount 2.13(a)(ii) Projected Indemnity Claim 2.13(c) Projected Indemnity Release Amount 2.13(c) Purchased Assets 2.3 Purchased Contracts 2.3(f) Purchased Intellectual Property 2.10(c2.3(g) Parent Preface Parent Financial Statements 3.07(bPurchased Leases 2.3(c)(ii) Parent SEC Documents 3.07(aPurchased Permits 2.3(n) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Purchased Real Property Leases 2.07(a2.3(d) Recommendation Withdrawal 4.03(a) Purchased Registered Intellectual Property 2.10(a3.13(a) Purchased Venture Interests 2.3(a) Purchased Venture Lease 2.3(c)(ii) Purchased Ventures 2.3(a) Purchased Ventures Accepted Liabilities 2.6 Purchased Ventures Balance Sheets 3.4(a)(iv) Purchaser Preamble Purchaser 401(k) Plan 5.3(d) Purchaser Allocation Notice 5.4(b) Purchaser Benefit Plans 5.3(b) Purchaser Claim 7.14(b) Purchaser Disclosure Schedules Article 4 Purchaser Indemnitee 6.2(b) Purchaser Material Adverse Effect 4.1(a) Regulation S-X 5.7 Related Party 1.08(a)(xxiv3.19(a) Representative Losses 10.01(eRemaining Escrow Deposit Amount 2.13(d)(i) Second Certificate Remaining Projected Indemnity Amount 2.13(d)(iii) Replacement Letter of Merger 1.01(cCredit 2.12(d) Second Effective Time 1.01(cResponsible Party 6.3(a) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(gRestricted Cash 2.3(s) Securities Act 2.04(bRetained Liabilities 2.6 Royalty-Free HMS License Agreement 2.9(g) Specified Stockholders 1.18 Stockholder Agreements 2.04(eSubleased Real Property 2.3(c)(ii) Stockholders Representative Preface Successful Completion 1.08(a)(xxvSubsequent Indemnity Release Amount 2.13(b) Superior Proposal 4.03(bSurvival Period Termination Date 6.1(a) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(aTangible Personal Property 2.3(h) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix)
(aTax Claim 5.4(c) Third Party Payments 1.08(a)(xxxClaim 6.3(a) Upfront Payments 1.08(xxxi)Title Insurance 5.6 Title Insurer 5.6 Transaction Recitals Transferred Employees 5.3(a) Unaudited Financial Statements 3.4(a)(ii) Venture Equity Interests 3.2(a) Venture Purchase 2.11 Venture Purchase Notice 2.11 Warranty Deed 2.10(c) Workaround 2.11
Appears in 1 contract
Sources: Asset Purchase Agreement
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Term Section 401(k) Plan 9.04 Accounting Firm 1.10(b) Adjustment Escrow Agent 1.13 Adjustment Escrow Amount 1.13 Agreement 4.03(dPreamble Audited Financial Statements 4.06(a) Agreement Preface Annual Net Sales 1.08(a)(iiBalance Sheet 4.06(a) Appraisal Rights Payments 7.02 Basket 7.03(aBalance Sheet Date 4.06(a) Black Out Period 5.06(gBase Consideration 1.02(c) Cancelled Shares 1.05(a) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) CERCLA 10.01 Certificate of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(vClaiming Party 11.19 Closing 1.11 Closing Residual Cash Consideration 1.02(c) Closing 1.02 Closing Date 1.02 Closing Residual Cash Certificate 1.11 Closing Shortfall Closing Merger Shares definition Consideration Calculation 1.08 Closing Statement 1.12 Combination Product 1.08(a)(xiii1.10(a) Commercially Reasonable Efforts 1.08(a)(viClosing Transactions 2.01 Company Preamble Company Employees 7.03 Company Registered IP 4.15(a) Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aSubsidiaries Section 1.1(a) Company Stock Plans 2.13(iConfidentiality Agreement 6.02 Consideration Schedule 1.09 Contracting Parties 11.21(a) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(a) Contingency Activities 1.08(iContracts 4.16(a) D&O Indemnified Parties 5.01(aCosts 7.02(b) D&O Expenses 7.02(b) D&O Indemnifiable Claim 7.02(b) D&O Indemnifying Party 7.02(b) D&O Indemnitee 7.02(b) D&O Tail 5.01(bPolicies 7.02(c) Defending Party 11.19 Designated Contacts 6.02 DGCL 1.01(a) Dispute Notice 1.12(b) Dispute Period 7.04(cRecitals Disclosure Schedules Article IV Disputed Items 1.10(b) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Effective Date Preface Efforts Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a) Financial Statements 2.05(a) Firm 12.18 First Shares 1.12 Effect 10.01 Effective Time 1.01(b) First Kolltan Commercial Milestone 1.08(b)(iiElectronic Delivery 11.15 Environmental Permits 4.12(b) First Merger 1.01(aEscrow Agent 1.13 Escrow Agreement 1.13 Excess Consideration 1.10(c) Filing Fees 6.03(a)4.06(a) Final Residual Cash Consideration 1.02(d) Financial Statements 4.06(a) Health Benefits 5.08 IND 1.08(a)(ixInformation Laws 4.20(e) IND Enabling Study 1.08(xHIPAA 4.20(e) Indemnity Cap 7.03(aHIPAA Regulations 4.20(e) Independent Accountant 1.12(b) Initial Registration Shares 5.06(a) Initiated 1.08(a)(xiIndividually Identifiable Health Information 4.20(e) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) Latest Balance Sheet 2.05(aRestrictive Covenant Agreement Recitals Lease 4.18(b) Leased Real Property 2.07(a4.18(b) Letter of Transmittal 1.06(d1.03 Liabilities 4.07 Management Restrictive Covenant Agreement Recitals Merger Recitals Merger Sub Preamble New Plans 7.03 Nonparty Affiliates 11.21(a) Licensed Intellectual Property 2.10(cObjections Statement 1.10(b) Lock-up Optionholder 1.04 Options 1.02(f) Parent Preamble Parent 401(k) Plan 9.04 Parent's Representatives 6.02 Paying Agent Agreement 1.06(d2.01(b) Lock-up Persons 1.06(dPer Share Portion 1.02(e) Marketing Approval 1.08(a)(xivPermits 4.09 Related Party 4.19 Releasee 11.21(b) Material Contracts 2.09(aReleasor 11.21(b) Mergers Representative Preamble Representative Reserve Fund 1.14 Restrictive Covenant Agreement Recitals Sample Working Capital Statement 1.08 Securities Act 5.07 Series A Common Merger Consideration 1.02(a) Series A Preferred Merger Consideration 1.02(a) Shortfall Consideration 1.10(d) Stockholder 1.03 Stockholder Group 9.06 Surviving Corporation 1.01(a) Merger Sub Preface METRIC Study 1.08(a)(xvTransfer Taxes 9.01(a) Merger Sub II Preface Milestone 1.08(b) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(d) Owned Intellectual Property 2.10(c) Parent Preface Parent Unaudited Financial Statements 3.07(b) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxix4.06(a)
(a) Third Party Payments 1.08(a)(xxx) Upfront Payments 1.08(xxxi)
Appears in 1 contract
Cross-Reference of Other Definitions. Each capitalized term listed below is defined in the corresponding Section of this Agreement: 280G Approval 5.04 280G Waiver 5.04 Acquisition Agreement 4.03(d2011 Budget 4.2(m) Agreement Preface Annual Net Sales 1.08(a)(iiBase Consideration 2.2(b)(i) Appraisal Rights Payments 7.02 Basket 7.03(aBuyer Preface Buyer Closing Certificate 3.2(e)(i) Black Out Period 5.06(gBuyer Indemnified Parties 8.2(a) Cancelled Shares 1.05(aBuyer's Transaction Expenses 9.6(b) Celldex Compound 1.08(a)(iii) Celldex Early Stage Compound 1.08(a)(iv) Certificate 1.06(c) Certificate Certificates of Merger 1.01(b) Claims Notice 7.04(b) Clinical Trial 1.08(a)(v2.1(b) Closing 1.02 2.13(a) Closing Consideration 2.2(b)(i) Closing Date 1.02 2.13(a) Closing Cash Certificate 1.11 Estimates 2.10 Closing Shortfall Closing Merger Shares definition Closing Statement 1.12 Combination Product 1.08(a)(xiiiTransactions 2.13(b) Commercially Reasonable Efforts 1.08(a)(vi) ▇▇▇▇▇▇▇ Recitals Company Preface Company Bank Accounts 2.24 Company Indemnification Provisions 5.01(aClosing Certificate 3.1(n)(i) Company Common Stock Plans 2.13(i2.2(a)(vi) Consideration Spreadsheet 1.05 Consideration Spreadsheet Losses 7.02(aCompany Intellectual Property 5.16(b) Contingency Activities 1.08(iConfidential Information 9.8(a) D&O Data Servers 5.16(m) DGCL 2.1(a) Director Indemnified Parties 5.01(a) D&O Tail 5.01(b) DGCL 1.01(a9.9(c) Dispute Notice 1.12(b) Dispute Period 7.04(cResolution Auditor 2.11(a) Dissenting Share 1.09 Dissenting Stockholder 1.09 DLLCA 1.01 Shares 2.9 DOJ 4.3(b) Effective Date Preface Efforts Time 2.1(b) Electronic Delivery 10.13 Employment Agreement Termination Agreements Recitals Escrow Agent 2.5 Escrow Agreement 2.5 Escrow Amount 2.5 Estimated Indebtedness 2.10 Exclusivity Period 1.08(a)(vii) European Market 1.08(a)(viii) Enforceability Exceptions 2.03(c) Estimated Closing Cash 1.11 Exchange Agent 1.06(a9.7 Final Consideration 2.2(b)(ii) Financial Statements 2.05(a5.6 FERPA 5.27 FTC 4.3(b) Firm 12.18 First Effective Time 1.01(bFully Indemnified Representations 8.2(c)(i) First Kolltan Commercial Milestone 1.08(b)(iiGeneral Cap 8.2(c)(iv) First Merger 1.01(aGeneral Deductible 8.2(c)(i) Health Benefits 5.08 IND 1.08(a)(ixGovernmental Approvals 3.1(d) IND Enabling Study 1.08(xHSR Act 3.1(d) Indemnity Cap 7.03(aIndemnifying Equityholder 8.2(a) Independent Accountant 1.12(bIndemnitee 8.2(e) Initial Registration Shares 5.06(aIndemnitor 8.2(e) Initiated 1.08(a)(xiInformation Systems 5.16(i) Investor Questionnaire 1.06(d) Kolltan Compound 1.08(a)(xii) Kolltan Product 1.08(a)(xiii) [**] [**] Latest Balance Sheet 2.05(a) 5.6 Leased Real Property 2.07(a5.9(b) Letter of Transmittal 1.06(d2.3 Licenses 5.19 Loss or Losses 8.2(a) Licensed Intellectual Property 2.10(cMerger 2.1(a) Lock-up Agreement 1.06(d) Lock-up Persons 1.06(d) Marketing Approval 1.08(a)(xiv) Material Contracts 2.09(a) Mergers 1.01(aMerger Consideration 2.2(b)(v) Merger Sub Preface METRIC Study 1.08(a)(xv[**] 8.2(c)(iii) Non-Compete Agreements Recitals Non-Consenting Stockholder Notice 4.3(c) Notice of Disagreement 2.11(a) Option Cancellation Agreement 2.4 Optionholder 2.4 Option Merger Sub II Preface Milestone 1.08(bConsideration 2.4 Options 2.2(b)(vi) Milestone Abandonment Notice 1.08(e) Milestone Notice 1.08(c)(ii) Milestone Payment 1.08(b) Nasdaq 6.01(s) Negotiation Period 7.04(d) Net Sales 1.08(a)(xvi) New Debt 2.06(c) New Debt Conversion Shares 1.14(b) New Debt Conversion Spreadsheet 1.05
(a) Other Active 1.08(a)(xvii) Outside Date 9.01(dOrdinary Course of Business 4.1(a) Owned Company Intellectual Property 2.10(c5.16(d) Parent Preface Parent Financial Statements 3.07(bParticipation Agreement 5.16(p) Parent SEC Documents 3.07(a) Parent Stock Value 1.08(a)(xi) Parties Preface Partnership Agreement 1.08(a)(xvii) Permits 2.15(c) Phase I Clinical Trial 1.08(a)(xx) Phase II Clinical Trial 1.08(a)(xxi) Phase III Clinical Trial 1.08(a)(xxii) Product Transferee 1.08(a)(xxiii) Proprietary Software 2.10(i) Prospectus Supplement 5.06(b) Real Property Leases 2.07(a) Recommendation Withdrawal 4.03(a) Registered Intellectual Property 2.10(a) Related Party 1.08(a)(xxiv) Representative Losses 10.01(e) Second Certificate of Merger 1.01(c) Second Effective Time 1.01(c) Second Merger 1.01 Section 280G Payments 5.04 Section 409A 2.13(g) Securities Act 2.04(b) Specified Stockholders 1.18 Stockholder Agreements 2.04(e) Stockholders Representative Preface Successful Completion 1.08(a)(xxv) Superior Proposal 4.03(b) Support Agreement Preface Survival Date 7.01 Surviving Company 1.01(a) Surviving Company Assets 1.08(a)(xxvi) Surviving Company Compound 1.08(a)(xxvii) Surviving Company Product 1.08(a)(xxviii) TAM Partnership 1.08(b)(iii) TAM Program 1.08(a)(xxixPayoff Letters 3.1(g)
(a) Third Party Payments 1.08(a)(xxxPer Share Portion 2.2(b)(iii) Upfront Payments 1.08(xxxi)Pre-Closing Tax Period 8.3(a) Preferred Stock 5.3 Preliminary Closing Statement 2.11(a) [**] 5.16(p) Released Claims 8.2(h) Released Parties 8.2(h) Representative Preface Representative Parties 10.14
Appears in 1 contract